MIF/CD74 axis is a target for metformin therapy in diabetic podocytopathy - real world evidence.
Endokrynol Pol
; 69(3): 264-268, 2018.
Article
en En
| MEDLINE
| ID: mdl-29952416
ABSTRACT
Introductionï¼To observe the effects of metformin on urinary excretion of MIF, CD74 and podocalyxin in type 2 diabetics and to explore its possible renoprotective mechanisms. METHODS:
202 uncontrolled type 2 diabetics, who were previously prescribed sulfonylurea monotherapy(n=100) or sulfonylurea in combination with metformin (n=102) were enrolled in the study. The amount of macrophage migration inhibitory factor(MIF) and CD74 in serum, urinary MIF to creatine ratio(UMCR), urinary CD74 to creatine ratio(UCCR), urinary albumin to creatine ratio(UACR) and urinary podocalyxin to creatine ratio (UPCR) were determined.RESULTS:
Metabolic parameters including fasting blood glucose, postprandial 2 hours blood glucose, hemoglobin A1c, MIF and CD74 in serum were comparable between the two groups. Moreover, metformin add-on therapy showed significantly better efficacy in reducing UMCR, UCCR, UPCR and UACR in comparison with those in sulfonylurea monotherapy group, respectively. UPCR had positive correlation with UACR, UMCR and UCCR (rï¼0.73, r=0.69, r=0.62, P < 0.01), respectively.CONCLUSIONS:
Metformin could present its podocyte-protective capacity in type 2 diabetics and the underlying mechanisms may be partly attributed to its effects in suppressing MIF-CD74 axis mediated inflammatory cascade response. < p > < /p >.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sialoglicoproteínas
/
Antígenos de Diferenciación de Linfocitos B
/
Antígenos de Histocompatibilidad Clase II
/
Factores Inhibidores de la Migración de Macrófagos
/
Oxidorreductasas Intramoleculares
/
Nefropatías Diabéticas
/
Metformina
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Endokrynol Pol
Año:
2018
Tipo del documento:
Article